FDA Accepts Aquestive’s Anaphylm Resubmission for Review
Bitget2026/10/15 11:01- FDA accepted Aquestive Therapeutics’ resubmitted application for Anaphylm, a sublingual film for severe allergic reactions, including anaphylaxis.
- The Class 2 review has a target decision date of March 16, 2027.
Disclaimer: The content of this article solely reflects the author's opinion and does not represent the platform in any capacity. This article is not intended to serve as a reference for making investment decisions.
You may also like
$6 billion acquisition! Medical giant Bausch Health plans to take a controlling stake in Surgery Partners (SGRY.US)
Boston Consulting Group plans to acquire a controlling stake in Surgery Partners for approximately $6 billions, at $20 per share; Bain Capital will retain a 40% stake, and the deal could be announced as early as Monday.
Solana added 22 million euros worth of stablecoins in one week.
SK Hynix plans to distribute special dividends totaling about $12 billion.
$40 billion spent on GPUs! Elon Musk says SpaceX (SPCX.US) off-balance-sheet financing is settled, slams "new cloud" sector will be a bloodbath
Elon Musk stated that SpaceX has completed a $40 billions debt transaction to purchase chips in support of its artificial intelligence (AI) initiatives.
Crypto prices
More
